Search
Massachusetts Paid Clinical Trials
A listing of 3204 clinical trials in Massachusetts actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1165 - 1176 of 3204
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Location
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Massachusetts is currently home to 3204 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Boston, Worcester, Springfield and Burlington. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Featured Therapy
Unique Treatment for High Blood Pressure
Worried about high blood pressure? Think beyond typical high blood pressure treatments.
People who may be candidates for this procedure:
• Are at least 18 years old
• Have been unable to manage their high blood pressure with medications or lifestyle changes alone¹
Learn about a safe and effective procedure that may help reduce high blood pressure. See if you qualify today.
¹ Kandzari DE, et al. J Am Coll Cardiol. Nov 7, 2023;82(19):1809-1823.
People who may be candidates for this procedure:
• Are at least 18 years old
• Have been unable to manage their high blood pressure with medications or lifestyle changes alone¹
Learn about a safe and effective procedure that may help reduce high blood pressure. See if you qualify today.
¹ Kandzari DE, et al. J Am Coll Cardiol. Nov 7, 2023;82(19):1809-1823.
Conditions:
High Blood Pressure
High Blood Pressure (& [Essential Hypertension])
High Blood Pressure (Hypertension).
Hypertension
Essential Hypertension
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Conditions:
Healthy
Healthy Volunteer Study
Featured Offer
Discover Affordable Semaglutide Providers
We Checked the Checkout Page on Every Semaglutide Provider. Here's What We Found.
There's a big difference between the price on a landing page and what you actually pay. We went all the way through checkout so you know exactly what to expect.
📋 5 providers ranked by true monthly cost
💵 Options starting as low as $149/month
🏥 Only licensed providers using FDA-registered pharmacies
⭐ Real Trustpilot scores included — including the ones with mixed reviews
🔒 Includes cancellation policy warnings so you don't get stuck
There's a big difference between the price on a landing page and what you actually pay. We went all the way through checkout so you know exactly what to expect.
📋 5 providers ranked by true monthly cost
💵 Options starting as low as $149/month
🏥 Only licensed providers using FDA-registered pharmacies
⭐ Real Trustpilot scores included — including the ones with mixed reviews
🔒 Includes cancellation policy warnings so you don't get stuck
Conditions:
Weight Loss
Morbid Obesity
Featured Offer
On Medicare? GLP-1's Covered By Medicare Part D [Found Partnership]
Found is now serving individuals who are 65-75 with GLP-1 support for weight care. You need Medicare Part D, must be 18 or older, and must meet BMI criteria when you start GLP-1 therapy:
- BMI 35 or higher, or
- BMI 30–34.99 with at least one qualifying condition (diastolic heart failure, uncontrolled hypertension, CKD stage 3a or higher, prediabetes, prior heart attack or stroke, symptomatic peripheral artery disease), or
- BMI 27–29.99 with prediabetes, prior heart attack/stroke, or symptomatic peripheral artery disease.
- BMI 35 or higher, or
- BMI 30–34.99 with at least one qualifying condition (diastolic heart failure, uncontrolled hypertension, CKD stage 3a or higher, prediabetes, prior heart attack or stroke, symptomatic peripheral artery disease), or
- BMI 27–29.99 with prediabetes, prior heart attack/stroke, or symptomatic peripheral artery disease.
Conditions:
Healthy
Overweight
Overweight and Obesity
Obesity
Overweight or Obesity
Featured Trial
Healthy Participants Needed (Colonoscopy + Cancer Screening)
Recruiting
Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
Conditions:
Healthy
Healthy Volunteers
Healthy Subjects
Healthy Volunteer
Healthy Participants
Ruxolitinib in Thrombocythemia and Polycythemia Vera
Recruiting
This research is being done to see if the drug ruxolitinib is effective in reducing the symptoms caused by low-risk essential thrombocythemia (ET) and polycythemia vera (PV).
- This research study involves the study drug Ruxolitinib.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/01/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Essential Thrombocythemia, Polycythemia Vera
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Recruiting
This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients with relapsed B-ALL are included in this study. Blinatumomab is an antibody, which is a protein that identifies and targets specific molecules in the body. Blinatumomab searches for and attaches itself to the cancer cell. Once attached, an immune response occu... Read More
Gender:
ALL
Ages:
Between 1 year and 30 years
Trial Updated:
07/01/2025
Locations: Tufts Children's Hospital, Boston, Massachusetts
Conditions: Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia
Genetic and Environmental Risk Factors for Hemorrhagic Stroke
Recruiting
The purpose of this study is to find risk factors for hemorrhagic stroke.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/01/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Stroke
APPROVE Trial: Evaluating a Prescription Digital Therapeutic for Treatment of OAB in Women
Recruiting
The APPROVE trial is a multi-centered, randomized controlled trial designed to assess differences in symptom improvement, quality of life, bladder symptoms, satisfaction with treatment and continued treatment efficacy in women with overactive bladder (OAB) randomized to a prescription digital therapeutic (PDTx) app called RiSolve compared to standard behavioral education (handouts).
Gender:
FEMALE
Ages:
22 years and above
Trial Updated:
06/30/2025
Locations: Curavit, Boston, Massachusetts
Conditions: Overactive Bladder (OAB), Urinary Urgency, Urinary Urge Incontinence (UUI), Nocturia, Urinary Frequency
A Phase 2 Study of Epcoritamab, Zanubrutinib, and Rituximab (EZR) for Treatment of Relapsed or Refractory Follicular Lymphoma or Marginal Zone Lymphoma
Recruiting
The purpose of this study is to determine how effective and safe the combination of epcoritamab, zanubrutinib, and rituximab is in treating participants with relapse or refractory Follicular Lymphoma (FL) or marginal zone lymphoma (MZL).
* The names of the study drugs involved in this research study are:
* Epcoritamab (a type of antibody)
* Zanubrutinib (a type of Bruton tyrosine kinase inhibitor)
* Rituximab (a type of monoclonal antibody)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/30/2025
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Follicular Lymphoma, Lymphoma, Non-Hodgkin Lymphoma, Relapsed Lymphoma, Refractory Lymphoma, Marginal Zone Lymphoma
Initial Resuscitation for Acute Kidney Injury in Cirrhosis
Recruiting
The goal of this interventional study is to evaluate two strategies for how to provide intravenous (IV) fluids for treating patients with acute kidney injury (AKI) in cirrhosis. The main question it aims to answer is: what is the safety, efficacy, and feasibility of providing a recommendation to use a Volume Assessment Guidance Algorithm (VAGA) or give standard of care doses of IV albumin?
Patients will be randomly assigned where their treating teams will receive a VAGA-based recommendation or... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/30/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Cirrhosis, Liver, Acute Kidney Injury, Hepatorenal Syndrome
Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Recruiting
The purpose of this study is to assess the safety, tolerability, drug levels, drug efficacy and determine the recommended dose of BMS-986497 as a monotherapy, in double combination with Azacitidine and in triple combination with Azacitidine and Venetoclax in participants with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/30/2025
Locations: Local Institution - 0007, Boston, Massachusetts
Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome
Avapritinib With Decitabine in Patients With SM-AHN
Recruiting
Systemic mastocytosis with an associated hematologic neoplasm (SM-AHN) is a challenging disease to treat. Targeted KIT inhibitors have been approved for this indication based on their ability to control the mastocytosis portion of the disease, but patients frequently experience progression of the concomitant myeloid malignancy (i.e. the AHN). Using a combination approach to treat both aspects of the disease has the potential to provide enhanced disease control; however, overlapping toxicity is a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/30/2025
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Systemic Mastocytosis With an Associated Hematologic Neoplasm
A Study of Participants With Cerebral Adrenoleukodystrophy (CALD) Treated With Elivaldogene Autotemcel
Recruiting
The main aim of this study is to assess and describe the safety outcomes, including newly diagnosed malignancies, of patients with CALD treated with eli-cel in the post-marketing setting (tradename Skysona) and to describe major functional disability (MFD)-free survival over time in participants with more advanced early active CALD. All enrolled participants with CALD treated with eli-cel in the post-marketing setting will be followed in this study for 15 years. No investigational drug product w... Read More
Gender:
MALE
Ages:
All
Trial Updated:
06/30/2025
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Cerebral Adrenoleukodystrophy (CALD)
Biliary Atresia Research Network Northeast
Recruiting
This is a multi-center retrospective chart review to compile a data repository of the management and outcomes of children with biliary atresia. Overall, investigators aim to evaluate which specific factors contribute to improved patient outcomes, to help guide potential improvements in patient care and resource utilization.
Gender:
ALL
Ages:
12 years and below
Trial Updated:
06/30/2025
Locations: Massachusetts General Hospital for Children, Boston, Massachusetts
Conditions: Biliary Atresia
A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Recruiting
The purpose of this study is to evaluate the mavacamten impact on myocardial structure with cardiac magnetic resonance imaging (CMR) in adult participants with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) \[New York Heart Association (NYHA) Functional Class II or III\].
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/30/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Cardiomyopathy, Hypertrophic
Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1
Recruiting
The purpose of this study is to evaluate the safety, tolerability, and efficacy of therapeutic vaccination with chimpanzee adenovirus ChAdOx1- and poxvirus modified vaccinia Ankara (MVA)-vectored conserved mosaic T-cell vaccines in a sequential regimen with the toll-like receptor 7 (TLR7) agonist vesatolimod (VES) and two broadly neutralizing antibodies (bNAbs) compared to placebo, to induce HIV-1 control during analytic treatment interruption (ATI).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/30/2025
Locations: Massachusetts General Hospital CRS (MGH CRS), Boston, Massachusetts
Conditions: HIV-1-infection